Armo reports additional Phase Ib data for AM0010 in pancreatic cancer

Armo BioSciences Inc. (Redwood City, Calif.) reported data from 34 evaluable patients with advanced pancreatic ductal adenocarcinoma in a Phase Ib trial in 352 patients with advanced solid tumors evaluating once-daily subcutaneous pegilodecakin (AM0010, PEG-IL-10) with or without FOLFOX chemotherapy.

In 15 evaluable patients, AM0010 as monotherapy led to an overall response rate (ORR) of 0% and a disease control rate (DCR) of 53%. Median progression-free survival (PFS) was 1.7 months, median overall survival (OS) was 3.8 months and the 1-year survival rate was 22%...